Beyond passive immunization: toward a nanoparticle-based IL-17 vaccine as first in class of future immune treatments

John Foerster (Lead / Corresponding author), Martin Bachman

    Research output: Contribution to journalArticlepeer-review

    8 Citations (Scopus)

    Abstract

    Nanoparticles occur naturally as part of repetitive molecular structures forming virus-like particles (VLPs). VLPs are powerful immune activators. Specifically, VLP can elicit a direct activation of B lymphocytes to trigger production of antibodies targeted at molecules chemically linked to the VLP. We here review recent data from genetics research, large-scale genomic sequencing, as well as clinical trials which suggest that a VLP-based vaccine against the signaling molecule IL-17 will be safe and effective in the common skin disease psoriasis, as well as other conditions. Active vaccination against IL-17 is capable of replacing the costly manufacture of antibodies currently in clinical use with huge implications for treatment availability and health economics.

    Original languageEnglish
    Pages (from-to)1361-1369
    Number of pages9
    JournalNanomedicine
    Volume10
    Issue number8
    DOIs
    Publication statusPublished - 2015

    Keywords

    • IL-17
    • Psoriasis
    • Vaccine
    • Virus-like particle

    Fingerprint Dive into the research topics of 'Beyond passive immunization: toward a nanoparticle-based IL-17 vaccine as first in class of future immune treatments'. Together they form a unique fingerprint.

    Cite this